Evaluation of Structurally Diverse Benzoazepines Clubbed with Coumarins as Mycobacterium tuberculosis Agents

Chemical Biology and Drug Design

Volumn 80, Issue 6, 2012, Pages 1003-1008

  Upadhyay, Kuldip ^a   Manvar, Atul ^b,g   Rawal, Kena ^c   Joshi, Sudhir ^d   Trivedi, Jalpa ^e   Chaniyara, Ravi ^f   Shah, Anamik ^b  

^a Gujarat Narmada Valley Fertilizers Company Limited   (India)

^b SAURASHTRA UNIVERSITY   (India)

^c Alembic Pharmaceuticals Limited   (India)

^d H & HB Kotak Institute of Science College Rajkot   (India)

^e ISF COLLEGE OF PHARMACY   (India)

^f Wockhardt Research Centre   (India)

^g UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Benzodiazepines; Benzothiazepines; Coumarins; H37Rv; Microplate alamar blue assay; Mtb

Indexed keywords

BENZODIAZEPINE DERIVATIVE; COUMARIN DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; BACTERIAL STRAIN; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; LETTER; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR HYBRIDIZATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; AZEPINES; COUMARINS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; THIAZEPINES;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84868139977     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2012.01436.x     Document Type: Letter

References (38)

1. Duncan K. (2003) Progress in TB drug development and what is still needed. Tuberculosis;83:201-207.
2. Ginsberg A.M., Spigelman M. (2007) Challenges in tuberculosis drug research and development. Nat Med;13:290-294.
3. Tripathi R.P., Bisht S.S., Ajay A., Sharma A., Misra M., Gupt M.Pd. (2012) Developments in chemical approaches to treat tuberculosis in the last decade. Curr Med Chem;30:488-517.
4. Gandhi N.R., Nunn P., Dheda K., Schaaf H.S., Zignol M., Van Soolingen D., Jensen P., Bayona J. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet;375:1830-1843.
5. Koul A., Arnoult E., Lounis N., Guillemont J., Andries K. (2011) The challenge of new drug discovery for tuberculosis. Nature;469:483-490.
6. Janin Y.L. (2007) Antituberculosis drugs: ten years of research. Bioorg Med Chem;15:2479-2513.
7. Mitton-Fry M.J., Hanna D. (2012) Current approaches to tuberculosis drug discovery and development, Series No. 14, Chapter 9. Neglected Disease and Drug Discovery. Cambridge, UK: RSC publishing.
8. Raviglione M.C., Smith I.M. (2007) XDR Tuberculosis-implications for global public health. N Engl J Med;356:656-659.
9. Moraski G.C., Markley L.D., Hipskind P.A., Boshoff H., Cho S., Franzblau S.G., Miller M.J. (2011) Advent of imidazo[1, 2-a]pyridine-3-carboxamides with potent multi- and extended drug resistant antituberculosis activity. ACS Med Chem Lett;2:466-470.
10. Dover L.G., Coxon G.D. (2011) Current status and research strategies in tuberculosis drug development. J Med Chem;54:6157-6165.
11. Yew W.W., Lange C., Leung C.C. (2011) Treatment of tuberculosis: update 2010. Eur Respir J;37:441-462.
12. Nayyar A., Jain R. (2005) Recent advances in new structural classes of anti-tuberculosis agents. Curr Med Chem;12:1873-1886.
13. Da Silva P.E.A., Palomino J.C. (2011) Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother;66:1417-1430.
14. Yew W.W., Cynamon M., Zhang Y. (2011) Emerging drugs for the treatment of tuberculosis. Expert Opin Emerging Drugs;16:1-21.
15. Upadhyay K., Bavishi A., Thakrar S., Radadiya A., Vala H., Parekh S., Bhavsar D., Savant M., Parmar M., Adlakha P., Shah A. (2011) Synthesis and biological evaluation of 4-styrylcoumarin derivatives as inhibitors of TNF-α and IL-6 with anti-tubercular activity. Bioorg Med Chem Lett;21:2547-2549.
16. Virsodia V., Shaikh M.S., Manvar A., Desai B., Parecha A., Loriya R., Dholariya K., Patel G., Vora V., Upadhyay K., Denish K., Shah A., Coutinho E.C. (2010) Screening for in vitro antimycobacterial activity and three-dimensional quantitative structure-activity relationship (3D-QSAR) study of 4-(arylamino)coumarin derivatives. Chem Biol Drug Des;76:412-424.
17. Manvar A., Malde A., Verma J., Virsodia V., Mishra A., Upadhyay K., Acharya H., Coutinho E.C., Shah A. (2008) Synthesis, anti-tubercular activity and 3D-QSAR study of coumarin-4-acetic acid benzylidene hydrazides. Eur J Med Chem;43:2395-2403.
18. Manvar A., Pissurlenkar R.R.S., Virsodia V., Upadhyay K., Manvar D., Mishra A., Acharya H., Parecha A., Dholakia C., Shah A., Coutinho E.C. (2011) Synthesis, in vitro antitubercular activity and 3D-QSAR study of 1, 4-dihydropyridines. Mol Divers;14:285-305.
19. Kharkar P.S., Desai B., Gaveria H., Varu B., Loriya R., Naliapara Y., Shah A., Kulkarni V.M. (2002) Three-dimensional quantitative structure-activity relationship of 1, 4-dihydropyridines as antitubercular agents. J Med Chem;45:4858-4867.
20. Dodia N., Shah A. (2000) Synthesis and antitubercular activity of some substituted 3-nitro and 3-bromo-4-hydroxy-2-quinolones. Indian J Heterocy Ch;10:69-70.
21. Virsodia V., Pissurlenkar R.R.S., Manvar D., Dholakia C., Adlakha P., Shah A., Coutinho E.C. (2008) Synthesis, screening for antitubercular activity and 3D-QSAR studies of substituted N-phenyl-6-methyl-2-oxo-4-phenyl-1, 2, 3, 4-tetrahydro-pyrimidine-5-carboxamides. Eur J Med Chem;43:2103-2115.
22. Sarkar D., Sarkar S., Joshi R.R., Khedkar V.M., Pissurlenkar R.R., Coutinho E.C., Shah A.K. (2011) 1, 6-Methyl-4-phenyl-5-(phenyl or cycloalkyl) carbamoyl-1, 2, 3, 4-tetrahydropyrimidin-2-one derivatives as antitubercular agents. PCT Int Appl, WO 2011/151701 A1 20111208.
23. Sarkar D., Sarkar S., Joshi R.R., Khedkar V.M., Pissurlenkar R.R., Coutinho E.C., Shah A.K. (2012) Preparation of 6-methyl-4-phenyl-5-(phenyl or cyclohexyl)carbamoyl-1, 2, 3, 4-tetrahydropyrimidin-2-one derivatives as antitubercular agents. Indian Pat Appl IN2010DE01244A20120302.
24. Currens M.J., Gulakowski R.J., Mariner J.M., Moran R.A., Buckheit R.W., Gustafson K.R., McMahon J.B., Boyd M.R. (1996) Antiviral activity and mechanism of action of calanolide A against the human immunodeficiency virus type-1. J Pharmacol Exp Ther;279:645-651.
25. 37Rv strains. Bioorg Med Chem Lett;21:4728-4731.
26. Dandia A., Sati M., Arya K., Sharma R., Loupyb A. (2003) Facile one pot microwave induced solvent-free synthesis and antifungal, antitubercular screening of spiro[1, 5]-benzothiazepin-2, 3'[3'H]indol-2[1'H]-ones. Chem Pharm Bull;51:1137-1141.
27. Dandia A., Upreti M., Rani B., Pant U.C., Gupta I.J. (1998) Synthesis and antimicrobial evaluation of some new fluorinated spiro[[1, 5]-benzothiazepin-2, 3'[3'H]-indol]-2'(1'H)-ones. J Fluorine Chem;91:171-174.
28. Kamal A., Reddy K.L., Devaiah V., Shankaraiah N., Reddy G.S.K., Raghvan S. (2007) Solid-phase synthesis of a library of pyrrolo[2, 1-c][1, 4]benzodiazepine-5, 11-diones with potential antitubercular activity. J Comb Chem;9:29-42.
29. Kabir M.S., Namjoshi O.A., Verma R., Polanowski R., Krueger S.M., Sherman D., Rott M.A., Schwan W.R., Monte A., Cook J.M. (2010) A new class of potential anti-tuberculosis agents: synthesis and preliminary evaluation of novel acrylic acid ethyl ester derivatives. Bioorg Med Chem;18:4178-4186.
30. 2+exchangers by 7-chloro-3, 5-dihydro-5-phenyl-1H-4, 1-benzothiazepine-2-one (CGP-37157). J Pharmacol Exp Ther;306:1050-1057.
31. Campiani G., Fiorini I., De Filippis M.P., Ciani S.M., Garofalo A., Nacci V., Giorgi G., Sega A., Botta M., Chiarini A., Budriesi R., Bruni G., Romeo M.R., Manzoni C., Mennini T. (1996) Cardiovascular characterization of pyrrolo[2, 1-d][1, 5]benzothiazepines derivatives binding selectively to the peripheral-type benzodiazepine receptor (PBR): from dual PBR affinity and calcium antagonist activity to novel and selective calcium entry blockers. J Med Chem;39:2933-2938.
32. Bolli M.H., Marfurt J., Grisostomi C., Boss C., Binkert C., Hess P., Treiber A., Thorin E., Morrison K., Buchmann S., Bur D., Ramuz H., Clozel M., Fischli W., Weller T. (2004) Novel benzo[1, 4]diazepin-2-one derivatives as endothelin receptor antagonists. J Med Chem;47:2776-2795.
33. Bariwal J.B., Upadhyay K.D., Manvar A.T., Trivedi J.C., Singh J.S., Jain K.S., Shah A.K. (2008) 1, 5-Benzothiazepine, a versatile pharmacophore: a review. Eur J Med Chem;43:2279-2290.
34. Mogilaih K., Sudhakar G.R. (2003) Synthesis of pyrazoline, pyrimidine and 1, 5-benzodiazepine derivatives of 1, 8-naphthyridine and evaluation of antibacterial activity. Indian J Chem;42B:636-640.
35. Kumar P.V., Rao V.R. (2008) Synthesis of pyrazoline, pyrimidine and 1, 5-benzodiazepine derivatives of 1, 8-naphthyridine and evaluation of antibacterial activity. Indian J Chem;47B:106-111.
36. Guo Q., Liu M.-L., Feng L.-S., Lv K., Guan G., Guo H.-Y., Xiao C.-L. (2011) Synthesis and in vitro antimycobacterial activity of fluoroquinolone derivatives containing a coumarin moiety. Arch Pharm Chem Life Sci;344:802-809.
37. Trivedi J.C., Bariwal J.B., Upadhyay K.D., Naliapara Y.T., Joshi S.K., Pannecouque C.C., Clercq E.C., Shah A.K. (2007) Improved and rapid synthesis of new coumarinyl chalcone derivatives and their antiviral activity. Tetrahedron Lett;48:8472-8474.
38. Kloss R.A., Wiener C. (1963) The reaction of 3-acyl-4-hydroxycoumarins with ammonium salts. J Org Chem;28:1671-1673.